Recent Finacing
Recent Raise
Solid Biosciences develops AAV-mediated gene therapies for Duchenne muscular dystrophy, advancing lead candidate SGT-001 into clinical development, pursuing corrective and disease-modifying platforms, disease research, assistive devices, and manufacturing.
